The latest price target for Zscaler (NASDAQ:ZS) was reported by Keybanc on June 25, 2026. The analyst firm set a price target for $176.00 expecting ZS to rise to within 12 months (a possible 15.79% ...

In 2026, tech companies tweaked and tuned the bet Bluetooth trackers to make it easier to keep tabs on your luggage, wallet and keys. The buzziest launch was Apple’s AirTag 2. But heavyweights Chipolo ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Posts from this topic will be added to your daily email digest and your homepage feed. For those of us who don’t ever seem to know where our keys or wallets have gone. For those of us who don’t ever ...

Much of the negativity appears to stem from the fiscal Q3 earnings release. Investors did not react well to the projected annual recurring revenue (ARR) range of 16% to 17% for fiscal 2027, well below ...

German biotech Tubulis has shared updated data from a phase 1 study of the antibody-drug conjugate (ADC) TUB-040, the star behind Gilead’s decision to buy the company for $3.15 billion upfront in ...

Zscaler's stock plummeted more than 30% on Wednesday for its worst day ever after reporting fiscal third-quarter earnings. The company lost two sales leaders, and finance chief Kevin Rubin said ...

Zscaler has been tapped as a favorite cybersecurity stock by some analysts, but investor optimism seems to have unraveled Wednesday after the company’s outlook for revenue in the current quarter fell ...

Stock futures tilted positive on Wednesday as a powerful tech rally countered ongoing geopolitical jitters. While recent U.S. military strikes in Iran sparked initial caution, broader market losses ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Safety and efficacy of BAT8006 in combination with BAT1308 in patients with advanced endometrial cancer. Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting ...

Zscaler (ZS) shares fell 14% in extended trading on Tuesday as mixed guidance from the cybersecurity company outweighed better-than-expected third-quarter results. For the period ending April 30, ...